Drug Cos. Say Rulings Don't Boost Actos Pay-For-Delay Suit
Three recent high-profile antitrust rulings should have no bearing on a pay-for-delay suit over Takeda Pharmaceutical Co.'s diabetes drug Actos, the defendants told a New York federal judge Friday, disputing plaintiffs'...To view the full article, register now.
Already a subscriber? Click here to view full article